2. Academic Validation
  3. Synthesis and Biological Evaluation of Pyrazole-Pyrimidones as a New Class of Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)

Synthesis and Biological Evaluation of Pyrazole-Pyrimidones as a New Class of Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)

  • J Med Chem. 2024 Aug 22;67(16):13891-13908. doi: 10.1021/acs.jmedchem.4c00685.
Christian Vaccarin 1 2,  Guido Veit 3,  Tamas Hegedus 4 5,  Odalys Torres 4,  Adriana Chilin 1,  Gergely L Lukacs 3,  Giovanni Marzaro 1
Affiliations

Affiliations

  • 1 Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.
  • 2 Center for Radiopharmaceutical Sciences, ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen, Switzerland.
  • 3 Department of Physiology and Biochemistry, McGill University, Montréal, QC H3G 1Y6, Canada.
  • 4 Institute of Biophysics and Radiation Biology, Semmelweis University, 1085 Budapest, Hungary.
  • 5 HUN-REN Biophysical Virology Research Group, Hungarian Research Network, Budapest 1052, Hungary.
PMID: 39137389 DOI: 10.1021/acs.jmedchem.4c00685
Abstract

Cystic fibrosis (CF) is caused by the functional expression defect of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Despite the recent success in CFTR Modulator development, the available correctors only partially restore the F508del-CFTR channel function, and several rare CF mutations show resistance to available drugs. We previously identified compound 4172 that synergistically rescued the F508del-CFTR folding defect in combination with the existing corrector drugs VX-809 and VX-661. Here, novel CFTR correctors were designed by applying a classical medicinal chemistry approach on the 4172 scaffold. Molecular docking and three-dimensional quantitative structure-activity relationship (3D-QSAR) studies were conducted to propose a plausible binding site and design more potent and effective analogs. We identified three optimized compounds, which, in combination with VX-809 and the investigational corrector 3151, increased the plasma membrane density and function of F508del-CFTR and other rare CFTR mutants resistant to the currently approved therapies.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z